NCT00415077

Brief Summary

The purpose of this study is to assess whether there is a significant difference in visual outcomes or corneal haze after surface ablation for moderate and high myopia in active duty service members treated with PRK, Mitomycin-C (MMC) PRK and LASEK.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
960

participants targeted

Target at P75+ for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2004

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

December 21, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 22, 2006

Completed
Last Updated

July 16, 2010

Status Verified

July 1, 2010

First QC Date

December 21, 2006

Last Update Submit

July 15, 2010

Conditions

Outcome Measures

Primary Outcomes (1)

  • Efficacy in terms of uncorrected visual acuity and post operative refraction. Safety in terms of maintenance of best spectacle corrected acuity within 2 lines of preoperative levels.

    12 months after surgery

Study Arms (3)

2

ACTIVE COMPARATOR

LASEK- laser-assisted subepithelial keratectomy

Procedure: MMC PRK

3

ACTIVE COMPARATOR

Mitomycin C PRK

Procedure: LASEK

1

ACTIVE COMPARATOR

PRK- Photorefractive keratectomy

Procedure: PRK

Interventions

PRKPROCEDURE

PRK

1
MMC PRKPROCEDURE

mitomycin C PRK

2
LASEKPROCEDURE

LASEK

3

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Informed consent.
  • Normal, healthy, active duty adults age 21 years or older. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
  • Manifest refractive spherical equivalent of greater than -4.00 diopters (D) up to -10.00 D.
  • Best spectacle corrected visual acuity of 20/20 or better in both eyes.
  • Demonstrated refractive stability, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50D during the 12-month period immediately preceding the baseline examination, as confirmed by clinical records.
  • Both eyes must fall in the same refraction group and there must be less than 1 D difference between eyes.
  • Soft contact lens users must have removed their lenses at least 2 weeks before baseline measurements. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least 4 weeks prior to baseline measurements and have 2 central keratometry readings and 2 manifest refractions taken at least 1 week apart that do not differ by more than 0.50 D in either meridian.
  • Access to transportation to meet the follow-up requirements.
  • Available for evaluation during the 1-year follow-up period.
  • Consent of the subject's command to participate in the study.

You may not qualify if:

  • Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. Women of childbearing age will take a urine pregnancy test before starting this study.
  • Residual, recurrent or active ocular diseases or corneal abnormalities in either eye such as keratoconus, iritis, uveitis, keratoconjunctivitis sicca, vernal conjunctivitis, lagophthalmos, corneal scarring, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.
  • Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
  • Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).
  • Any physical or mental impairment that would preclude participation in any of the examinations.
  • Prior refractive or ocular surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Walter Reed Army Medical Center, Center For Refractive Surgery

Washington D.C., District of Columbia, 20307, United States

Location

MeSH Terms

Interventions

Keratectomy, Subepithelial, Laser-Assisted

Intervention Hierarchy (Ancestors)

Corneal Surgery, LaserLaser TherapyTherapeuticsAblation TechniquesSurgical Procedures, OperativeKeratectomyRefractive Surgical ProceduresOphthalmologic Surgical Procedures

Study Officials

  • KRAIG S BOWER, MD

    DIRECTOR, CENTER FOR REFRACTIVE SURGERY WALTER REED ARMY MEDICAL CENTER

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED

Study Record Dates

First Submitted

December 21, 2006

First Posted

December 22, 2006

Study Start

June 1, 2004

Last Updated

July 16, 2010

Record last verified: 2010-07

Locations